Prosecution Insights
Last updated: November 04, 2026
Application No. 18/292,145

SOUND-GUIDED ASSESSMENT AND LOCALIZATION OF AIR LEAK AND ROBOTIC SYSTEM TO LOCATE AND REPAIR PULMONARY AIR LEAK

Non-Final OA §103§112
Filed
Jan 25, 2024
Priority
Jul 27, 2021 — provisional 63/226,119 +2 more
Examiner
KASHYAP, ESHA PRAKASH
Art Unit
3783
Tech Center
3700 — Mechanical Engineering & Manufacturing
Assignee
Stanford University
OA Round
1 (Non-Final)
100%
Grant Probability
Favorable
1-2
OA Rounds
9m
Est. Remaining
99%
With Interview

Examiner Intelligence

Grants 100% — above average
100%
Career Allowance Rate
1 granted / 1 resolved
+30.0% vs TC avg
Minimal +0% lift
Without
With
+0.0%
Interview Lift
resolved cases with interview
Typical timeline
3y 6m
Avg Prosecution
37 currently pending
Career history
55
Total Applications
across all art units

Statute-Specific Performance

§103
54.0%
+14.0% vs TC avg
§102
33.1%
-6.9% vs TC avg
§112
12.2%
-27.8% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1 resolved cases

Office Action

§103 §112
Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Claims 26-28 and 30-45 are examined in this office action. Claim Objections Claim 4 objected to because of the following informalities: In line 1 "operative" should read "operatively". Appropriate correction is required. Claim Rejections - 35 USC § 112 The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claims 26-28 and 30-42 rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. Claim 26 recites the limitation "the location of an air leak" in 10. There is insufficient antecedent basis for this limitation in the claim. Claim 28 recites the limitation "the posterior side" and “the anterior side” in line 2. There is insufficient antecedent basis for this limitation in the claim. All remaining claims are rejected as they depend from independent claim 26. Claim Rejections - 35 USC § 103 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. Claim(s) 26, 27, 30-34, and 38 is/are rejected under 35 U.S.C. 103 as being unpatentable over Whitman et al. (US Patent No. 6,368,286 B1) in view of Hulings et al. (US Pub No. 20220249024 A1) and in further view of Salamini et al. (CN 109310338 A). Regarding claim 26, Whitman in view of Huling and Salmini disclose a non-invasive apparatus for detecting pulmonary air leaks of a human patient (Whitman, "Method and device for detecting life-threatening pneumothorax …" - Abstract), comprising: a garment (Whitman, self-adhesive patch 25, Fig. 9) having a plurality of sensors (Whitman, transducers 24, Fig. 9) adapted to detect acoustic signals (Whitman, "… digital sound signal [is] received from transducers 24 in such a way as to detect the presence of a pneumothorax." - Col. 4 Line 3) produced by a pulmonary air leak internal to a wearer of the garment (Whitman, "…the device … is used to detect an unnatural pocket of air in the thoracic cavity." - Col. 2 Line 67); an amplifier (Whitman, central processing unit 20, Fig. 9) operatively engaged to the plurality of sensors (Whitman, "The novel transducer 22 of the present invention includes a series of … transducers … wired in parallel, for example with wires 26 to the central processor 20." - Col. 3 Line 54), the amplifier configured to amplify the acoustic signals detected by the plurality of sensors and to thereby produce amplified acoustic signals (Whitman, "The software also shifts the frequencies to maximize the auditory detection of the pneumothorax." - Col. 4 Line 9); an acoustic analyzer (Whitman, central processing unit 20, Fig. 9) adapted to receive the amplified acoustic signals produced by the amplifier (Whitman, "The basic function of the software is to receive a digital sound signal received from transducers 24 …" - Col. 4v Line 1), the acoustic analyzer being programmed with sound localization algorithms (Whitman, "The software uses data obtained during product development using either a neural network, genetic algorithms, or rule-based decision making." - Col. 4 Line 13) to determine the location of an air leak represented by the acoustic signals detected by the plurality of sensors (Whitman, "For gross location of a suspected area, a filtered electronic listening device will be used which coupled high-sensitivity listening device to the exterior of the body (ex. Transducers 24)." - Col. 4 Line 36); and the location of an air leak represented by the acoustic signals detected by the plurality of sensors (Whitman, "For gross location of a suspected area, a filtered electronic listening device will be used which coupled high-sensitivity listening device to the exterior of the body (ex. Transducers 24)." - Col. 4 Line 36) Whitman does not expressly disclose a therapeutic delivery system operatively coupled to the garment, the therapeutic delivery system including a steerable therapeutic applicator having a longitudinal body with a proximal end, a distal end and a length therebetween, the therapeutic applicator further including a plurality of channels extending along at least a portion of the length of the longitudinal body, a first channel of the plurality of channels being configured to receive and deliver a therapeutic to. Hulings teaches a therapeutic delivery system (therapy electrodes 1414, Fig. 14A) operatively coupled to the garment (belt 1450, Fig. 14A). Therefore, it would have been obvious, before the effective filing date of the claimed invention, to modify the apparatus of Whitman to include a therapeutic delivery system operatively coupled to the garment as taught by Hulings to deliver one or more therapeutic shocks to the patient (Hulings, Para [0013]). Hulings does not expressly disclose the therapeutic delivery system including a steerable therapeutic applicator having a longitudinal body with a proximal end, a distal end and a length therebetween, the therapeutic applicator further including a plurality of channels extending along at least a portion of the length of the longitudinal body, a first channel of the plurality of channels being configured to receive and deliver a therapeutic to. Salamini teaches the therapeutic delivery system (See annotated Fig. 3) including a steerable therapeutic applicator having a longitudinal body with a proximal end (See annotated Fig. 3), a distal end (See annotated Fig. 3) and a length therebetween (See annotated Fig. 3), the therapeutic applicator further including a plurality of channels extending along at least a portion of the length of the longitudinal body (sensor port 112, Fig. 3) (delivery/sampling lumen 110, Fig. 3), a first channel of the plurality of channels being configured to receive and deliver a therapeutic ("… the controller is configured to determine at least one parameter … and is further configured to obtain the location of the sensor within the body of the subject." - Page 1). PNG media_image1.png 720 540 media_image1.png Greyscale Therefore, it would have been obvious, before the effective filing date of the claimed invention, to modify the apparatus of Whitman to include the therapeutic delivery system including a steerable therapeutic applicator having a longitudinal body with a proximal end, a distal end and a length therebetween, the therapeutic applicator further including a plurality of channels extending along at least a portion of the length of the longitudinal body, a first channel of the plurality of channels being configured to receive and deliver a therapeutic to as taught by Salamini so fluid can be injected (Salamini, Para [0131]). Regarding claim 27, Whitman in view of Huling and Salmini disclose the apparatus (Whitman, "Method and device for detecting life-threatening pneumothorax …" - Abstract) as recited above, wherein the plurality of sensors (Whitman, transducers 24, Fig. 9) is arranged in an array (Whitman, "The array of transducers …" - Col. 3 Line 63). Regarding claim 30, Whitman in view of Huling and Salmini disclose the apparatus (Whitman, "Method and device for detecting life-threatening pneumothorax …" - Abstract) as recited above, wherein the acoustic analyzer (Whitman, central processing unit 20, Fig. 9) is a computer (Fig. 9) programmed to use the sound localization algorithms (Whitman, "The software uses data obtained during product development using either a neural network, genetic algorithms, or rule-based decision making." - Col. 4 Line 13) to assess differences in time- arrival and intensity of the acoustic signals detected by the plurality of sensors (Whitman, "… the strength of the reflection in association with the time that the reflection is received will allow the system/user to determine the nature of the boundary." - Col. 3 Line 8). Regarding claim 31, Whitman in view of Huling and Salmini disclose the apparatus (Whitman, "Method and device for detecting life-threatening pneumothorax …" - Abstract) as recited above, wherein the computer is programmed with noise filtering algorithms (Whitman, "The software processes a digital sound signal by filtering out frequencies far away from a set point, which is the frequency of air bubbling out of the lung." - Col. 4 Line 4) to isolate acoustic signals unique to an air leak (Whitman, "The transducers 24 algebraically eliminate motion artifacts and room noise, as shown in FIG. 4." - Col. 4 Line 7). Regarding claim 32, Whitman in view of Huling and Salmini disclose the apparatus (Whitman, "Method and device for detecting life-threatening pneumothorax …" - Abstract) as recited above, wherein the computer is programmed to filter out ambient noise (Whitman, "The transducers 24 algebraically eliminate motion artifact and room noise, as shown in FIG. 4." - Col. 4 Line 7), as well as heartbeat and other background noises of a wearer of the garment (Whitman, "… the filtering of the signal before presentation to the user will allow large low-frequency sounds such as the heart to be attenuated …" - Col. 4 Line 32). Regarding claim 33, Whitman in view of Huling and Salmini disclose the apparatus (Whitman, "Method and device for detecting life-threatening pneumothorax …" - Abstract) as recited above, wherein Whitman does not expressly disclose that the plurality of channels of the therapeutic applicator further includes a second channel configured to receive a microphone for air leak sound recording and a third channel configured to receive an optical fiber for optical guidance of the therapeutic applicator inside a wearer's chest cavity. Salamini teaches that the plurality of channels of the therapeutic applicator (as shown in Fig. 3) further includes a second channel (sensor port 112, Fig. 3) configured to receive a microphone for air leak sound recording ("… the measurable parameter may use a sensor (… a microphone, etc.) to detect." - Para [0019]) and a third channel ("However, there may be more than one infusion/sampling lumen and/or more than one sensor." - Para [0081]) configured to receive an optical fiber for optical guidance of the therapeutic applicator ("… three-tube cavity device and a double-cavity device each having two fiber optic cables." - Para [0209], Figs. 45-46) inside a wearer's chest cavity (“The location of the sensor within the vascular system of the subject's body.” – Page 3). Therefore, it would have been obvious, before the effective filing date of the claimed invention, to modify the apparatus of Whitman to include that the plurality of channels of the therapeutic applicator further includes a second channel configured to receive a microphone for air leak sound recording and a third channel configured to receive an optical fiber for optical guidance of the therapeutic applicator inside a wearer's chest cavity as taught by Salamini so the system has been navigated to its desired position (Salamini, Para [0158]). Regarding claim 34, Whitman in view of Huling and Salmini disclose the apparatus (Whitman, "Method and device for detecting life-threatening pneumothorax …" - Abstract) as recited above, wherein Whitman does not expressly disclose that the first channel has a diameter of 2 mm, the second channel has a diameter of 1 mm and the third channel has a diameter of 1 mm. Salamini teaches that the first channel has a diameter of 2 mm ("… diameter or size of the flow path can be from about .01mm to 2.0mm." - Para [0145]), the second channel has a diameter of 1 mm ("… the diameter or size of the cross section of the flow path can be from bout .1mm to 1.0mm." - Para [0145]) and the third channel has a diameter of 1 mm ("… the diameter or size of the cross section of the flow path can be from bout .1mm to 1.0mm." - Para [0145]). Therefore, it would have been obvious, before the effective filing date of the claimed invention, to modify the apparatus of Whitman to include that the first channel has a diameter of 2 mm, the second channel has a diameter of 1 mm and the third channel has a diameter of 1 mm as taught by Salamini so fluid can be injected (Salamini, Para [0131]). Regarding claim 38, Whitman in view of Huling and Salmini disclose the apparatus (Whitman, "Method and device for detecting life-threatening pneumothorax …" - Abstract) as recited above, wherein Whitman does not expressly disclose that the therapeutic applicator is configured to target and deliver therapeutic by optoacoustic guidance. Salamini teaches that the therapeutic applicator (Fig. 3) is configured to target and deliver therapeutic by optoacoustic guidance ("… the measurable parameter may use a sensor (… a light sensor … a microphone etc.) to detect … whether the catheter tip is advanced to a desired location …" - Para [0019]). Therefore, it would have been obvious, before the effective filing date of the claimed invention, to modify the apparatus of Whitman to include that the therapeutic applicator is configured to target and deliver therapeutic by optoacoustic guidance as taught by Salamini so the system has been navigated to its desired position (Salamini, Para [0158]). Claim(s) 28 is/are rejected under 35 U.S.C. 103 as being unpatentable over Whitman et al. (US Patent No. 6,368,286 B1) in view of Hulings et al. (US Pub No. 20220249024 A1) and Salamini et al. (CN 109310338 A) and in further view of Ghosh (US Pub No. 20200352470 A1). Regarding claim 28, Whitman in view of Huling and Salmini disclose the apparatus (Whitman, "Method and device for detecting life-threatening pneumothorax …" - Abstract) as recited above, wherein Whitman does not expressly disclose that the plurality of sensors is arranged in a 3x3 array or a 6x6 array on the posterior side and/or the anterior side of the garment. Ghosh teaches that the plurality of sensors (electrodes 112, Fig. 3) is arranged in a 3x3 array or a 6x6 array (as shown in Fig. 3) on the posterior side and/or the anterior side of the garment (vest 114, Fig. 3). Therefore, it would have been obvious, before the effective filing date of the claimed invention, to modify the apparatus of Whitman to include that the plurality of sensors is arranged in a 3x3 array or a 6x6 array on the posterior side and/or the anterior side of the garment as taught by Ghosh to delivery cardiac therapy thereto (Ghosh, Para [0098]). Claim(s) 35, 36, and 42 is/are rejected under 35 U.S.C. 103 as being unpatentable over Whitman et al. (US Patent No. 6,368,286 B1) in view of Hulings et al. (US Pub No. 20220249024 A1) and Salamini et al. (CN 109310338 A) and in further view of Kesner et al. (WO 2011137336 A1). Regarding claim 35, Whitman in view of Huling and Salmini disclose the apparatus (Whitman, "Method and device for detecting life-threatening pneumothorax …" - Abstract) as recited above, wherein Whitman does not expressly disclose that the therapeutic applicator is steered by visual servoing based upon information collected via the optical fiber received in the third channel. Salamini teaches the optical fiber received in the third channel ("However, there may be more than one infusion/sampling lumen and/or more than one sensor." - Para [0081]) ("… three-tube cavity device and a double-cavity device each having two fiber optic cables." - Para [0209], Figs. 45-46). Therefore, it would have been obvious, before the effective filing date of the claimed invention, to modify the apparatus of Whitman to include the optical fiber received in the third channel as taught by Salamini so the system has been navigated to its desired position (Salamini, Para [0158]). Salamini does not expressly disclose that the therapeutic applicator is steered by visual servoing based upon information collected via the optical fiber. Kesner teaches that the therapeutic applicator (catheter system 104, Fig. 1) is steered by visual servoing ("… 3D ultrasound visual servoing system that tracks the tissue and commands the catheter to follow the motion." - Para [0101]) based upon information collected via the optical fiber ("… a first and a second fiber optic cable extend through the hollow catheter guide-wire into the sensor." - Para [0104]). Therefore, it would have been obvious, before the effective filing date of the claimed invention, to modify the apparatus of Whitman to include that the therapeutic applicator is steered by visual servoing based upon information collected via the optical fiber as taught by Kesner to make contact with the target tissue (Kesner, Para [0104]). Regarding claim 36, Whitman in view of Huling and Salmini disclose the apparatus (Whitman, "Method and device for detecting life-threatening pneumothorax …" - Abstract) as recited above, wherein Whitman does not expressly disclose that the therapeutic delivery system further includes a motor and motor controller operatively engaged to the therapeutic applicator. Kesner teaches that the therapeutic delivery system further includes a motor ("… the catheter can be controlled and actuated by one or more actuators (e.g., motors …" - Para [0012]) and motor controller operatively engaged to the therapeutic applicator (controller 154, Fig. 1). Therefore, it would have been obvious, before the effective filing date of the claimed invention, to modify the apparatus of Whitman to include that the therapeutic delivery system further includes a motor and motor controller operatively engaged to the therapeutic applicator as taught by Kesner to control the tip (Kesner, Para [0012]). Regarding claim 42, Whitman in view of Huling and Salmini disclose the apparatus (Whitman, "Method and device for detecting life-threatening pneumothorax …" - Abstract) as recited above, wherein Whitman does not expressly disclose that the therapeutic applicator is steered manually or using computer vision guidance. Kesner teaches that the therapeutic applicator is steered manually or using computer vision guidance ("… 3D ultrasound visual servoing system that tracks the tissue and commands the catheter to follow the motion." - Para [0101]). Therefore, it would have been obvious, before the effective filing date of the claimed invention, to modify the apparatus of Whitman to include that the therapeutic applicator is steered manually or using computer vision guidance as taught by Kesner to make contact with the target tissue (Kesner, Para [0104]). Claim(s) 37 is/are rejected under 35 U.S.C. 103 as being unpatentable over Whitman et al. (US Patent No. 6,368,286 B1) in view of Hulings et al. (US Pub No. 20220249024 A1) and Salamini et al. (CN 109310338 A) and in further view of Landon et al. (CN 114585329 A). Regarding claim 37, Whitman in view of Huling and Salmini disclose the apparatus (Whitman, "Method and device for detecting life-threatening pneumothorax …" - Abstract) as recited above, wherein Whitman does not expressly disclose that the therapeutic applicator includes a plurality of pulling wires along the length of the body thereof, the therapeutic applicator being steerable by at least one motor attached to the pulling wires. Landon teaches that the therapeutic applicator includes a plurality of pulling wires along the length of the body thereof (pulling wires 138, 140) (delivery system 10, Fig. 1), the therapeutic applicator being steerable by at least one motor attached to the pulling wires ("The motor 500 can be configured to operate the track assembly 20, for example, by actuating the traction wire 138 or 140." - Para [0412]). Therefore, it would have been obvious, before the effective filing date of the claimed invention, to modify the apparatus of Whitman to include that the therapeutic applicator includes a plurality of pulling wires along the length of the body thereof, the therapeutic applicator being steerable by at least one motor attached to the pulling wires as taught by Landon for catheter delivery (Landon, Para [0140]). Claim(s) 39 and 40 is/are rejected under 35 U.S.C. 103 as being unpatentable over Whitman et al. (US Patent No. 6,368,286 B1) in view of Hulings et al. (US Pub No. 20220249024 A1) and Salamini et al. (CN 109310338 A) and in further view of Krimsky (EP 3299058 A1). Regarding claim 39, Whitman in view of Huling and Salmini disclose the apparatus (Whitman, "Method and device for detecting life-threatening pneumothorax …" - Abstract) as recited above, wherein Whitman does not expressly disclose that the first channel of the therapeutic applicator is preloaded with therapeutic for air leak repair. Krimsky teaches that the first channel of the therapeutic applicator is preloaded with therapeutic ("… guiding catheter through the bronchoscope, dispensing medium to the target area from a distal end of the catheter …" - Para [0007])) for air leak repair ("… the medium is at least one of a … sealant." - Para [0014]). Therefore, it would have been obvious, before the effective filing date of the claimed invention, to modify the apparatus of Whitman to include that the first channel of the therapeutic applicator is preloaded with therapeutic for air leak repair as taught by Krimsky to bind openings in the lung walls (Krimsky, Para [0079]). Regarding claim 40, Whitman in view of Huling and Salmini disclose the apparatus (Whitman, "Method and device for detecting life-threatening pneumothorax …" - Abstract) as recited above, wherein an air leak represented by the acoustic signals detected by the plurality of sensors (Whitman, "… digital sound signal [is] received from transducers 24 in such a way as to detect the presence of a pneumothorax." - Col. 4 Line 3). Whitman does not expressly disclose that the therapeutic is a biosealant hydrogel composition adapted to seal an air leak. Krimsky teaches that the therapeutic is a biosealant hydrogel composition adapted to seal an air leak ("… guiding catheter through the bronchoscope, dispensing medium to the target area from the a distal end of the catheter …" - Para [0007])) ("… the medium is at least one of a … sealant." - Para [0014]). Therefore, it would have been obvious, before the effective filing date of the claimed invention, to modify the apparatus of Whitman to include that the therapeutic is a biosealant hydrogel composition adapted to seal an air leak as taught by Krimsky to bind openings in the lung walls (Krimsky, Para [0079]). Claim(s) 41 is/are rejected under 35 U.S.C. 103 as being unpatentable over Whitman et al. (US Patent No. 6,368,286 B1) in view of Hulings et al. (US Pub No. 20220249024 A1) and Salamini et al. (CN 109310338 A) and in further view of Ginn (US Pub No. 20050085856 A1). Regarding claim 41, Whitman in view of Huling and Salmini disclose the apparatus (Whitman, "Method and device for detecting life-threatening pneumothorax …" - Abstract) as recited above, wherein Whitman does not expressly disclose that the plurality of channels comprises flexible polymeric conduits with guidewire disks attached to an outer surface of a distal end of each of the conduits. Salamini teaches that the plurality of channels comprises flexible polymeric conduits (as shown in Fig. 3). Therefore, it would have been obvious, before the effective filing date of the claimed invention, to modify the apparatus of Whitman to include that the plurality of channels comprises flexible polymeric conduits as taught by Salamini so the system has been navigated to its desired position (Salamini, Para [0158]). Salamini does not expressly disclose conduits with guidewire disks attached to an outer surface of a distal end of each of the conduits. Ginn teaches conduits with guidewire disks (guidewire disks 43, Fig. 9) attached to an outer surface of a distal end of each of the conduits (guidewire tube 34, Fig. 9). Therefore, it would have been obvious, before the effective filing date of the claimed invention, to modify the apparatus of Whitman to include conduits with guidewire disks attached to an outer surface of a distal end of each of the conduits as taught by Ginn for a more precise positioning of the sealing element (Ginn, Para [0020]). Claim(s) 43 is/are rejected under 35 U.S.C. 103 as being unpatentable over Whitman et al. (US Patent No. 6,368,286 B1) in view of Krimsky (EP 3299058 A1) and in further view of Salamini et al. (CN 109310338 A). Regarding claim 43, Whitman in view of Krimsky and Salamini disclose a method for treating pulmonary air leaks of a human patient (Whitman, "Method and device for detecting life-threatening pneumothorax …" - Abstract), the method comprises the steps of: determining a location of a pulmonary air leak (Whitman, "For gross location of a suspected area, a filtered electronic listening device will be used which coupled high-sensitivity listening device to the exterior of the body (ex. Transducers 24)." - Col. 4 Line 36); visualizing the determined location of the pulmonary air leak (Whitman, "The reflection from the chest is analyzed and presented to the user either auditorily or visually. For example, a display unit as shown in FIG. 8 can be adapted for display of the ultrasound results." - Col. Line); Whitman does not expressly disclose inserting a therapeutic applicator into a patient's chest; a microphone operatively coupled to the therapeutic applicator; steering the therapeutic applicator to the determined location of the pulmonary air leak; an optical fiber imaging probe operatively coupled to the therapeutic applicator; and delivering a therapeutic to the determined location of the pulmonary air leak. Krimsky teaches inserting a therapeutic applicator into a patient's chest (Navigate bronchoscope with EM sensor through lungs to target 612, Fig. 6); steering the therapeutic applicator to the determined location of the pulmonary air leak (Navigate bronchoscope with EM sensor through lungs to target 612, Fig. 6); and delivering a therapeutic to the determined location of the pulmonary air leak (Dispense medium to isolated segment of the lungs 622, Fig. 6). Therefore, it would have been obvious, before the effective filing date of the claimed invention, to modify the apparatus of Whitman to include inserting a therapeutic applicator into a patient's chest; steering the therapeutic applicator to the determined location of the pulmonary air leak; and delivering a therapeutic to the determined location of the pulmonary air leak as taught by Krimsky to bind openings in the lung walls (Krimsky, Para [0079]). Krimsky does not expressly disclose a microphone operatively coupled to the therapeutic applicator; an optical fiber imaging probe operatively coupled to the therapeutic applicator. Salamini teaches a microphone operatively coupled to the therapeutic applicator (sensor port 112, Fig. 3) ("… the measurable parameter may use a sensor (… a microphone, etc.) to detect." - Para [0019]); an optical fiber imaging probe operatively coupled to the therapeutic applicator ("However, there may be more than one infusion/sampling lumen and/or more than one sensor." - Para [0081]) ("… three-tube cavity device and a double-cavity device each having two fiber optic cables." - Para [0209], Figs. 45-46). Therefore, it would have been obvious, before the effective filing date of the claimed invention, to modify the apparatus of Whitman to include a microphone operatively coupled to the therapeutic applicator; an optical fiber imaging probe operatively coupled to the therapeutic applicator as taught by Salamini so the system has been navigated to its desired position (Salamini, Para [0158]). Claim(s) 44 is/are rejected under 35 U.S.C. 103 as being unpatentable over Whitman et al. (US Patent No. 6,368,286 B1) in view of Krimsky (EP 3299058 A1) and Salamini et al. (CN 109310338 A) and in further view of Hulings et al. (US Pub No. 20220249024 A1). Regarding claim 44, Whitman in view of Krimsky, Salamini, and Hulings disclose the method (Whitman, "Method and device for detecting life-threatening pneumothorax …" - Abstract), as recited above, wherein Whitman does not expressly disclose that the therapeutic applicator is operative engaged to a garment adapted to be worn by the patient. Hulings teaches that the therapeutic applicator (therapy electrodes 1414, Fig. 14A) is operative engaged to a garment adapted to be worn by the patient (belt 1450, Fig. 14A). Therefore, it would have been obvious, before the effective filing date of the claimed invention, to modify the apparatus of Whitman to include that the therapeutic applicator is operative engaged to a garment adapted to be worn by the patient as taught by Hulings to deliver one or more therapeutic shocks to the patient (Hulings, Para [0013]). Claim(s) 45 is/are rejected under 35 U.S.C. 103 as being unpatentable over Whitman et al. (US Patent No. 6,368,286 B1) in view of Krimsky (EP 3299058 A1) and Salamini et al. (CN 109310338 A) and in further view of Ghosh (US Pub No. 20200352470 A1). Regarding claim 45, Whitman in view of Krimsky, Salamini, and Hulings disclose the method (Whitman, "Method and device for detecting life-threatening pneumothorax …" - Abstract), as recited above, wherein Whitman does not expressly disclose that the garment is in the form of a vest or chest strap. Ghosh teaches that the garment is in the form of a vest or chest strap (vest 114, Fig. 3). Therefore, it would have been obvious, before the effective filing date of the claimed invention, to modify the apparatus of Whitman to include that the garment is in the form of a vest or chest strap as taught by Ghosh to deliver cardiac thereby thereto (Ghosh, Para [0098]). Conclusion Any inquiry concerning this communication or earlier communications from the examiner should be directed to ESHA P KASHYAP whose telephone number is (571)272-9890. The examiner can normally be reached Monday - Friday 8:30am - 5:00pm. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Chelsea Stinson can be reached at (571) 270-1744. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /ESHA PRAKASH KASHYAP/ Examiner, Art Unit 3783 /CHELSEA E STINSON/ Supervisory Patent Examiner, Art Unit 3783
Read full office action

Prosecution Timeline

Jan 25, 2024
Application Filed
Sep 22, 2026
Non-Final Rejection mailed — §103, §112 (current)

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
100%
Grant Probability
99%
With Interview (+0.0%)
3y 6m (~9m remaining)
Median Time to Grant
Low
PTA Risk
Based on 1 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month